Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-088514 · Präparat HOS-083663
7
sulfamethoxazole for the
treatment of Pneumocystis
jirovecii pneumonia (PCP) and
toxoplasmosis have not been
studied and should be avoided.
ANTIFUNGALS
Fluconazole/Lamivudine Interaction not studied. As only limited data are
Fluconazole/Zidovudine Zidovudine AUC 74% available the clinical
(400 mg once daily/200 mg significance is not known.
thrice daily) (UGT inhibition) Monitor for signs of
zidovudine toxicity (see
section 4.8).
ANTIMYCOBACTERIALS
Rifampicin/Lamivudine Interaction not studied. Insufficient data to
Rifampicin/Zidovudine (600 Zidovudine AUC 48% recommend dosage
mg once daily/200 mg thrice adjustment.
daily) (UGT induction)
ANTICONVULSANTS
Phenobarbital/Lamivudine Interaction not studied. Insufficient data to
Phenobarbital/Zidovudine Interaction not studied. recommend dosage
adjustment.
Potential to slightly decrease
zidovudine plasma
concentrations through UGT
induction.
Phenytoin/Lamivudine Interaction not studied. Monitor phenytoin
Phenytoin/Zidovudine Phenytoin AUC concentrations.
Valproic acid/Lamivudine Interaction not studied. As only limited data are
Valproic acid/Zidovudine Zidovudine AUC 80% available the clinical
(250 mg or 500 mg thrice significance is not known.
daily/100 mg thrice daily)
(UGT inhibition) Monitor for signs of
zidovudine toxicity (see
section 4.8).
ANTIHISTAMINES (HISTAMINE H1 RECEPTOR ANTAGONISTS)
Ranitidine/Lamivudine Interaction not studied. No dosage adjustment
necessary.
Clinically significant
interaction unlikely. Ranitidine
eliminated only in part by renal
organic cation transport system.
Ranitidine/Zidovudine Interaction not studied
Cimetidine/Lamivudine Interaction not studied. No dosage adjustment
necessary.
Clinically significant
interaction unlikely.
Cimetidine eliminated only in
part by renal organic cation
transport system.
Cimetidine/Zidovudine Interaction not studied.
CYTOTOXICS
Cladribine/Lamivudine Interaction not studied Therefore the concomitant use
of lamivudine with cladribine
In vitro lamivudine inhibits the is not recommended
intracellular phosphorylation of (see section 4.4)
cladribine leading to a potential
risk of cladribine loss of
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) fluconazole (HOS-087945) phenobarbital (HOS-085617) phenytoin (HOS-084531) valproic acid (HOS-088515) histamine (HOS-088516) ranitidine (HOS-085660) cimetidine (HOS-085835) cladribine (HOS-085842)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage 80bfcdbc676c074809992c973802a382b624f4a50bfeaaede637578173acc0cf · Zeichen 3740–7470 im Abschnitt
Wechselwirkungen · Trizivir
TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-108566 · Präparat HOS-093047
Phenytoin/Abacavir Interaction not studied. Insufficient data to
recommend dosage
Potential to slightly decrease adjustment.
abacavir plasma concentrations
through UGT induction. Monitor phenytoin
Phenytoin/Lamivudine Interaction not studied. concentrations.
Phenytoin/Zidovudine Phenytoin AUC
Valproic acid/Abacavir Interaction not studied.
As only limited data are
Valproic acid/Lamivudine available the clinical
Interaction not studied.
Valproic acid/Zidovudine Zidovudine AUC 80%significance is not known.
(250 mg or 500 mg thrice Monitor for signs of
daily/100 mg thrice daily)
(UGT inhibition) zidovudine toxicity (see
section 4.8).
ANTIHISTAMINES (HISTAMINE H2 RECEPTOR ANTAGONISTS)
Ranitidine/Abacavir Interaction not studied. No dosage adjustment
Ranitidine/Lamivudine Interaction not studied. necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenytoin (HOS-084531) valproic acid (HOS-088515) histamine (HOS-088516) ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T14:10:00Z · SHA-256 0fa44d429f9cace08dce2fd9d8c4f2ed838fc8cb0ed1b7cfc79bd6b9caa26349 · Passage 409c5f9ee2c015f2b6f723303036c2b2acdd238bc9098136b7a883f2d611ce36 · Zeichen 7108–8354 im Abschnitt
Wechselwirkungen · Akynzeo
Akynzeo 300 mg/0.5 mg hard capsules · Abschnitt 4.5 · PDF-Seite 6
HOS-130705 · Präparat HOS-096947
Netupitant/palonosetron capsules are unlikely to interact with medicinal products which are P-gp
substrates. Netupitant is not a substrate for P-gp. When netupitant was administered on Day 8 of a
12-day regimen of digoxin, no changes in digoxin pharmacokinetics were observed.
Inhibition of the efflux transported BCRP and glucuronidation isozyme UGT2B7 by netupitant and
its metabolites is unlikely and, if it occurs, of scarce clinical relevance.
In vitro data shows that netupitant inhibits UGT2B7, the magnitude of such an effect in the clinical
setting is not established. Caution is recommended when netupitant is combined with an oral
substrate of this enzyme (e.g.zidovudine, valproic acid, morphine).
In vitro data suggests that netupitant inhibits the efflux of transporter BCRP. The clinical relevance
of this effect is not established.
In vitro data show that netupitant is a P-gp inhibitor. In a study performed in healthy volunteers,
netupitant does not affect the exposure of digoxin, a P-gp substrate, whereas it increases its Cmax by
1.09 fold [90%CI 0.9-1.31]. It is not excluded that this effect may be more marked, and then clinically
relevant, in cancer patients, notably those having abnormal renal function. Therefore, caution is
recommended when netupitant is combined with digoxin or with other P-gp substrates such as
dabigatran, or colchicine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): digoxin (HOS-086172) zidovudine (HOS-085837) valproic acid (HOS-088515) morphine (HOS-086053) dabigatran (HOS-112096) colchicine (HOS-086147)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T11:52:00Z · SHA-256 d3ff78e9e4d5b08bc98e527fab724082b02f5be1899a4d4f9c683d723854e46c · Passage 96b7ee6eabe5208fbc56455ff673b439029e4001003dd7cdd5c63d4eabcfef30 · Zeichen 5376–6746 im Abschnitt
Wechselwirkungen · Akynzeo
Akynzeo 235 mg/0.25 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 22
HOS-130744 · Präparat HOS-096947
Fosnetupitant/palonosetron powder for concentrate for solution for infusion is unlikely to interact with
medicinal products which are P-gp substrates. Netupitant is not a substrate for P-gp. When netupitant
was administered on Day 8 of a 12-day regimen of digoxin, no changes in digoxin pharmacokinetics
were observed.
Inhibition of the efflux transporter BCRP by fosenetupitant netupitant and its metabolites is unlikely
and, if it occurs, of scarce clinical relevance.
In vitro data shows that fosnetupitant inhibits UGT2B7 / UGT2B15 and netupitant inhibits UGT2B7,
the magnitude of such an effect in the clinical setting is not established. Caution is therefore
recommended when netupitant and fosnetupitant is combined with an oral substrate of this enzyme
(e.g. zidovudine, valproic acid, morphine).
In vitro data suggests that netupitant inhibits the efflux of transporter BCRP. The clinical relevance of
this effect is not established.
In vitro data show that netupitant is a P-gp inhibitor. In a study performed in healthy volunteers,
netupitant does not affect the exposure of digoxin, a P-gp substrate, whereas it increases its Cmax by
1.09 fold [90%CI 0.9-1.31]. It is not excluded that this effect may be more marked, and then clinically
relevant, in cancer patients, notably those having abnormal renal function. Therefore, caution is
recommended when netupitant is combined with digoxin or with other P-gp substrates such as
dabigatran, or colchicine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dabigatran (HOS-112096) colchicine (HOS-086147) fosnetupitant (HOS-130728) digoxin (HOS-086172) zidovudine (HOS-085837) valproic acid (HOS-088515) morphine (HOS-086053)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T11:52:00Z · SHA-256 d3ff78e9e4d5b08bc98e527fab724082b02f5be1899a4d4f9c683d723854e46c · Passage 5599ee427a1e50bd2272fe198378f2c70e90fb72bcd0d5255d25c484c7630b39 · Zeichen 5421–6886 im Abschnitt
Wechselwirkungen · Akynzeo
Akynzeo 235 mg/0.25 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 40
HOS-130786 · Präparat HOS-096947
Additional interactions
Fosnetupitant/palonosetron concentrate for solution for infusion is unlikely to interact with medicinal
products which are P-gp substrates. Netupitant is not a substrate for P-gp. When netupitant was
administered on Day 8 of a 12-day regimen of digoxin, no changes in digoxin pharmacokinetics were
observed.
Inhibition of the efflux transporter BCRP by fosenetupitant, netupitant and its metabolites is unlikely
and, if it occurs, of scarce clinical relevance.
In vitro data shows that fosnetupitant inhibits UGT2B7 / UGT2B15 and netupitant inhibits UGT2B7,
the magnitude of such an effect in the clinical setting is not established. Caution is therefore
recommended when netupitant and fosnetupitant is combined with an oral substrate of this enzyme
(e.g. zidovudine, valproic acid, morphine).
In vitro data suggests that netupitant inhibits the efflux of transporter BCRP. The clinical relevance of
this effect is not established.
In vitro data show that netupitant is a P-gp inhibitor. In a study performed in healthy volunteers,
netupitant does not affect the exposure of digoxin, a P-gp substrate, whereas it increases its Cmax by
1.09 fold [90%CI 0.9-1.31]. It is not excluded that this effect may be more marked, and then clinically
relevant, in cancer patients, notably those having abnormal renal function. Therefore, caution is
recommended when netupitant is combined with digoxin or with other P-gp substrates such as
dabigatran, or colchicine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fosnetupitant (HOS-130728) digoxin (HOS-086172) zidovudine (HOS-085837) valproic acid (HOS-088515) morphine (HOS-086053) dabigatran (HOS-112096) colchicine (HOS-086147)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T11:52:00Z · SHA-256 d3ff78e9e4d5b08bc98e527fab724082b02f5be1899a4d4f9c683d723854e46c · Passage 8c215b1fbfe8f1f9dbaf112d918c68f8d01887bfa8a5614b7eb096350ae2d47a · Zeichen 5397–6876 im Abschnitt
Wechselwirkungen · Akynzeo
Akynzeo 300 mg/0.5 mg oral suspension in sachet · Abschnitt 4.5 · PDF-Seite 57
HOS-130825 · Präparat HOS-096947
In vitro data shows that netupitant inhibits UGT2B7, the magnitude of such an effect in the clinical
setting is not established. Caution is recommended when netupitant is combined with an oral
substrate of this enzyme (e.g.zidovudine, valproic acid, morphine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): zidovudine (HOS-085837) valproic acid (HOS-088515) morphine (HOS-086053)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-25T11:52:00Z · SHA-256 d3ff78e9e4d5b08bc98e527fab724082b02f5be1899a4d4f9c683d723854e46c · Passage 1e5c1a5d2728ea8c998200ac04c6958893ed6e30956cc333e5d79dd3aa17397a · Zeichen 5817–6077 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.